Eli Lilly (NYSE:LLY)
Historical Stock Chart
1 Month : From Nov 2019 to Dec 2019
By Michael Dabaie
Eli Lilly and Co. (LLY) said Taltz met the primary and all major secondary endpoints in the COAST-X placebo-controlled Phase 3 study in non-radiographic axial spondyloarthritis.
In the study, Taltz improved the signs and symptoms of non-radiographic axSpA as measured by ASAS40, as well as reduced inflammation on MRI, the company said.
Axial spondyloarthritis is a chronic inflammatory disease affecting predominantly the sacroiliac joints and the spine skeleton and is estimated to affect 4.5 million adults worldwide.
A total of 303 adult patients with active nr-axSpA were randomized to receive Taltz 80 mg subcutaneously every four weeks or every two weeks, or placebo. At week 16, 35% of patients treated every four weeks and 40% of patients treated every two weeks achieved ASAS40 response, compared with 19% with placebo. At week 52, 30% treated every four weeks and 31% treated every two weeks achieved ASAS40 response, compared with 13% with placebo.
Write to Michael Dabaie at firstname.lastname@example.org
(END) Dow Jones Newswires
November 12, 2019 08:13 ET (13:13 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.